SCHEMBL4628419

SCHEMBL4628419

NC(=Nc1cc(Br)ccc1Br)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
RAB9A P51151 6/20 0.43
SCN2A Q99250 5/20 0.43
NPC1 O15118 5/20 0.43
SCN5A Q14524 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MALT1 Q9UDY8 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
MIF P14174 1/20 0.39
HPGD P15428 1/20 0.38
PSMD14 O00487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628470 0.87 SCN2A (0.55) RAB9ASCN2ANPC1SCN5APKM
SCHEMBL4628973 0.71 SCN2A (0.77) SMN1; SMN2RAB9ASCN2ANPC1SCN5A
SCHEMBL4628413 0.69 GPR35 (0.49) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL4629412 0.68 P2RX4 (0.56) MEN1KMT2ALMNAALDH1A1HPGD
SCHEMBL9117609 0.68 LMNA (0.63) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL11877875 0.68 PLAU (0.50) PKMMAPTPOLB
SCHEMBL4628494 0.68 SCN2A (0.80) SMN1; SMN2RAB9ASCN2ANPC1SCN5A
SCHEMBL4627551 0.68 POLB (0.59) SMN1; SMN2RAB9ASCN2ANPC1SCN5A
SCHEMBL15047786 0.67 MAPT (0.67) SMN1; SMN2MEN1KMT2AKDM4ELMNA
SCHEMBL8507058 0.65 LMNA (0.59) SMN1; SMN2RAB9ASCN2ANPC1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SMN1; SMN2 53/4885RAB9A 617/4885SCN2A 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.